Trial · NCT07288112
DOC1021 Dendritic Cell Immunotherapy for Refractory Melanoma
NCT07288112, Phase 1, Phase 2, Recruiting, Diakonos Oncology Corporation
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. DOC1021 Dendritic Cell Immunotherapy for Refractory Melanoma. Trials, record NCT07288112. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07288112
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- DOC1021 Dendritic Cell Immunotherapy for Refractory Melanoma
- NCT number
- NCT07288112
- Status
- Recruiting
- Phases
- Phase 1, Phase 2
- Enrollment
- 35 participants, estimated
- Lead sponsor
- Diakonos Oncology Corporation
- Conditions
- Refractory Melanoma
- Interventions
- DOC1021, Tumor resection, pIFN (peginterferon alfa-2a)
- First posted
- 2025-12-17
- Last updated
- 2026-09-09
Source ClinicalTrials.gov
Registered outcomes10
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Phase I: To evaluate the number of dose limiting toxicities reported | From time of first DOC1021 dose administration to 6 weeks later | |
| Primary | Phase II: To evaluate the objective response rate (ORR) as the proportion of patients with a confirmed complete response (CR) or partial response (PR) to treatment, as per RECIST 1.1 criteria | 5 years | |
| Secondary | Overall survival (time in months from the date of study enrollment until death for from any cause) | 5 years | |
| Secondary | Time in months from the first documentation of complete or partial response to disease progression by RECIST 1.1 criteria or death, whichever occurs first. | 5 years | Duration of Response (DOR) |
| Secondary | Time in months from date of study enrollment to disease progression by RECIST 1.1 criteria or death from any cause | 5 years | Progression-free survival (PFS) |
| Secondary | The proportion of participants with complete response, partial response, or stable disease out of the total eligible and evaluable participants. | 5 years | Disease control rate (DCR) |
| Secondary | Number of participants with adverse events as assessed by CTCAE v5.0 | 3 years | |
| Secondary | To evaluate the objective response rate (ORR) as the proportion of patients with a confirmed complete response (CR) or partial response (PR) to treatment, as per immune-related response criteria (iRECIST) | 5 years | |
| Other | Health-related quality of life in all participants as assessed by EORTC Quality of Life Questionnaire Cancer QLC-C30 (Cancer 30-items). | 2 years | All items are scored 1 (worse outcome) to 4 (better outcome) or 1 (worse outcome) to 7 (better outcome). All of the scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response level. |
| Other | Change in circulating tumor DNA (ctDNA) levels after DOC1021 administration. | 5 years |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07288112
GET https://conductscience.org/api/trials/v1/NCT07288112/registered